Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 2, 2014, Pages

  Zhao, J ^a   Zhang, X S ^a   Zhang, S ^a  

^a CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; BLEBBISTATIN; CAMPTOTHECIN; CYCLOHEXIMIDE; DOXORUBICIN; ETOPOSIDE; MITOMYCIN; MONASTROL; TRICHOSTATIN A; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL FUNCTION; DRUG COMBINATION; DRUG DESIGN; DRUG EFFECT; DRUG RESEARCH; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; LARGE CELL LYMPHOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

EID: 84896802719     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.79     Document Type: Article

References (38)

1. Shoemaker, R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813-823 (2006).
2. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
3. Iorio, F. et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. USA 107, 14621-14626 (2010).
4. Iskar, M. et al. Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding. Mol. Syst. Biol. 9, 662 (2013).
5. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
6. Risch, N. & Merikangas, K. The future of genetic studies of complex human diseases. Science 273, 1516-1517 (1996).
7. Manolio, T.A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
8. Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B. & Sorger, P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006).
9. Santoro, A., Bonadonna, G., Bonfante, V. & Valagussa, P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N. Engl. J. Med. 306, 770-775 (1982).
10. Kitano, H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 5, 202-210 (2007).
11. Borisy, A.A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA 100, 7977-7982 (2003).
12. Cottarel, G. & Wierzbowski, J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 25, 547-555 (2007).
13. Lehár, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659-666 (2009).
14. Zimmermann, G.R., Lehár, J. & Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34-42 (2007).
15. Finan, B. et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847-1856 (2012).
16. Zhao, X.M., Iskar, M., Zeller, G., Kuhn, M., van Noort, V. & Bork, P. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput. Biol. 7, e1002323 (2011).
17. Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111-128 (2009).
18. Jin, G., Zhao, H., Zhou, X. & Wong, S.T. An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data. Bioinformatics 27, i310-i316 (2011).
19. Wu, Z., & Chen, L. A network-based approach for identifying effective drug combination. In (eds. Chen, L., Zhang, X.S., Wu, L.Y. & Wang, Y.) The Third International Symposium on Optimization and Systems Biology (OSB 09) 207-213 (2009).
20. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
21. Csermely, P., Agoston, V. & Pongor, S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 26, 178-182 (2005).
22. Keith, C.T., Borisy, A.A. & Stockwell, B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71-78 (2005).
23. Furuse, K. et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-smallcell lung cancer. J. Clin. Oncol. 17, 2692-2699 (1999).
24. Iyer, V.N. & Szybalski, W. A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc. Natl. Acad. Sci. USA 50, 355-362 (1963).
25. Latt, S.A. Sister chromatid exchanges, indices of human chromosome damage and repair: detection by fluorescence and induction by mitomycin C. Proc. Natl. Acad. Sci. USA 71, 3162-3166 (1974).
26. Williams, S.D., Birch, R., Einhorn, L.H., Irwin, L., Greco, F.A. & Loehrer, P.J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316, 1435-1440 (1987).
27. Noda, K. et al.; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85-91 (2002).
28. Maliga, Z., Kapoor, T.M. & Mitchison, T.J. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem. Biol. 9, 989-996 (2002).
29. Kapoor, T.M., Mayer, T.U., Coughlin, M.L. & Mitchison, T.J. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J. Cell Biol. 150, 975-988 (2000).
30. DeBonis, S. et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 42, 338-349 (2003).
31. Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174-17179 (1990).
32. Murad, A.M., Santiago, F.F., Petroianu, A., Rocha, P.R., Rodrigues, M.A. & Rausch, M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72, 37-41 (1993).
33. Ueda, K., Cardarelli, C., Gottesman, M.M. & Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 84, 3004-3008 (1987).
34. Shimaoka, K., Schoenfeld, D.A., DeWys, W.D., Creech, R.H. & DeConti, R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56, 2155-2160 (1985).
35. Kawamoto, S. & Hidaka, H. 1-(5-Isoquinolinesulfonyl)-2- methylpiperazine (H-7) is a selective inhibitor of protein kinase C in rabbit platelets. Biochem. Biophys. Res. Commun. 125, 258-264 (1984).
36. Reyland, M.E. Protein kinase C is a tonic negative regulator of steroidogenesis and steroid hydroxylase gene expression in Y1 adrenal cells and functions independently of protein kinase A. Mol. Endocrinol. 7, 1021-1030 (1993).
37. Winter, G.E. et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat. Chem. Biol. 8, 905-912 (2012).
38. Beisser, D., Klau, G.W., Dandekar, T., Müller, T. & Dittrich, M.T. BioNet: an R-Package for the functional analysis of biological networks. Bioinformatics 26, 1129-1130 (2010).